Skip to main content

Table 1 Baseline characteristics of study cases with febuxostat and allopurinol

From: Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study

CharacteristicsAcute renal failure with febuxostat as the suspected drug (n = 317)Acute renal failure with allopurinol as the suspected drug (n = 1008)
Age, years, mean (SD)68.0 (15.0)67.0 (14.5)
Age, n (%)
 19–4427 (8.5)79 (7.8)
 45–6483 (26.2)306 (30.4)
 65–7481 (25.6)270 (26.8)
 ≥ 75126 (39.7)353 (35.0)
Sex, n (%)
 Male172 (54.3)577 (57.2)
 Female145 (45.7)431 (42.8)
Reporter qualification, n (%)
 Healthcare professional281 (88.6)863 (85.6)
 Not a healthcare professional17 (5.4)41 (4.1)
 Unknown19 (6.0)104 (10.3)
 The only suspected drug, n (%)184 (58.0)447 (44.3)
Continent, n (%)
 North America115 (36.3)233 (23.1)
 Europe115 (36.3)489 (48.5)
 Asia82 (25.9)237 (23.5)
 Other regions*5 (1.6)49 (4.9)
Seriousness of ARF
 Death22 (6.9)97 (9.6)
 Life-threatening event32 (10.1)111 (11.0)
 Disability/incapacity18 (5.7)13 (1.3)
 Hospitalization (caused or prolonged)115 (36.3)482 (47.8)
 Others70 (22.1)111 (11.0)
 Unknown60 (18.9)194 (19.2)
  1. *Included Oceania and Africa